The Coronavirus Immunotherapy Consortium (CoVIC) is a global public-private partnership based out of the Center for Infectious Disease and Vaccine Research at the La Jolla Institute for Immunology.[1] CoVIC's principal investigator is Erica Saphire.
The stated purpose of the consortium is to “accelerate discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2.”[2]
History
CoVIC is a continuation of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), which was previously formed to collect donations of antibodies against Ebola and Lassa viruses.[3]
Organization
Consortium partners include:[4]
- Carterra
- Duke University
- La Jolla Institute for Immunology
- Nexelis
- Texas Biomedical Research Institute
- University of Texas Medical Branch
- University of Wisconsin-Madison
Funding
CoVIC is funded by the COVID-19 Therapeutics Accelerator, GHR Foundation, and the National Institute of Allergy and Infectious Diseases (NIAID).[2:1] NIAID funding came as a supplement to a Center for Excellence in Therapeutic Research (CETR) grant to Dr. Saphire (U19 142790-02S1).
External links
Contact. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from https://web.archive.org/web/20230119213903/https://covic.lji.org/contact/ ↩︎
About CoVIC. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from https://web.archive.org/web/20230119213917/https://covic.lji.org/about/ ↩︎ ↩︎
CoVIC Formation and Mission. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from http://archive.today/2023.01.19-215137/https://covic.lji.org/about/vic-as-a-model-for-covic/ ↩︎
Partners. Coronavirus Immunotherapy Consortium. Retrieved January 19, 2023, from http://archive.today/2023.01.19-220616/https://covic.lji.org/partners/ ↩︎
